Glaxo blueprints major new Shanghai research center

GlaxoSmithKline has named Dr. Jingwu Zang to run a major new R&D center in Shanghai which will focus on developing a new generation of neurodegenerative drugs. Glaxo plans to concentrate all of its research on such diseases as Parkinson's and Alzheimer's at the center, taking its drugs from target identification through late-stage trials. The center is designed to grow into one of the largest research efforts within Glaxo's multinational operations.

"We intend to be part of a future in which the phrase 'discovered in China' is heard as often as 'made in China' is heard today," said Glaxo research chief Moncef Slaoui.

- check out the release

Related stories:
China says former drug czar accepted bribes. Report
Bridge garners $35M to expand China operations. Report

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.